Related Experiment Video
Updated: Feb 3, 2026

Author Spotlight: Revolutionizing Remote Surgery with Augmented Reality and Robotics for Enhanced Precision and Accessibility
Published on: August 9, 2024
Cardiac Surgery Compared With Antibiotics Only in Patients Developing Infective Endocarditis After Transcatheter
Norman Mangner1, Sergey Leontyev2, Felix J Woitek1
11 Department of Internal Medicine and Cardiology Heart Center Dresden Technical University Dresden Dresden Germany.
Insights
Infective endocarditis after transcatheter aortic valve replacement carries high mortality. Cardiac surgery with antibiotics did not significantly improve 1-year survival compared to antibiotics alone in this high-risk patient group.
Area of Science:
- Cardiology
- Infectious Diseases
- Surgical Outcomes
Background:
- Infective endocarditis (IE) post-transcatheter aortic valve replacement (TAVR) is a severe complication with high mortality.
- Optimal treatment strategies for IE post-TAVR remain debated, particularly the role of cardiac surgery.
Purpose of the Study:
- To compare the 1-year mortality rates between patients with IE post-TAVR treated with cardiac surgery and antibiotics versus those treated with antibiotics alone.
- To identify predictors of 1-year mortality in patients with IE post-TAVR.
Main Methods:
- Retrospective analysis of patients who developed IE after TAVR.
- Comparison of 1-year all-cause mortality between a group undergoing IE-cardiac surgery (IE-CS) and a group receiving IE-antibiotic therapy only (IE-ABx).
- Cox regression analysis to identify factors associated with mortality.
Main Results:
- In an unmatched cohort, 1-year mortality was similar (65% vs. 68.2%, P=0.802). The IE-ABx group was older with more comorbidities.
- In a matched cohort, 1-year mortality remained similar (65% vs. 75%, P=0.490).
- Factors predicting 1-year mortality included any indication for surgery (HR 6.20), sepsis on admission (HR 4.03), and mitral regurgitation ≥2 (HR 2.91).
Conclusions:
- Mortality in IE post-TAVR is predicted by IE severity and mitral regurgitation.
- Cardiac surgery did not offer a significant 1-year mortality benefit over medical management with antibiotics alone in this small, high-risk cohort.
- Individualized treatment decisions by a multidisciplinary team are crucial for optimizing patient care.
Abstract:
Background Infective endocarditis ( IE ) after transcatheter aortic valve replacement is a devastating complication associated with a high mortality. Our objective was to determine the impact of cardiac surgery (CS) and antibiotics ( IE - CS ) compared with medical treatment with antibiotics only ( IE - AB x) on 1-year mortality in patients developing IE after transcatheter aortic valve replacement. Methods and Results Patients developing IE after transcatheter aortic valve replacement were included in this retrospective analysis. All-cause 1-year mortality was the primary end point. A total of 20 patients underwent IE - CS compared with 44 patients treated by IE - AB x. In this unmatched cohort, patients treated by IE - AB x were older ( P=0.006), had a higher Society of Thoracic Surgeons score ( P=0.029), and more often had severe chronic kidney disease ( P=0.037). One-year mortality was not different between groups ( IE -CS versus IE-ABx, 65% versus 68.2%; P=0.802). The rate of any complication during treatment was higher in the IE - CS group ( P=0.024). In a matched cohort, baseline characteristics were not significantly different. All-cause 1-year mortality was not different between groups ( IE -CS versus IE-ABx, 65% versus 75%; P=0.490). A Cox regression analysis revealed any indication for surgery (hazard ratio, 6.20; 95% confidence interval, 1.80-21.41; P=0.004), sepsis on admission (hazard ratio, 4.03; 95% confidence interval, 1.97-8.24; P<0.001), and mitral regurgitation ≥2 (hazard ratio, 2.91; 95% confidence interval, 1.33-6.37) as factors associated with 1-year mortality. Conclusions In patients developing IE after transcatheter aortic valve replacement, mortality was predicted by the severity of IE and concomitant mitral regurgitation. In this small, and therefore statistically limited, but high-risk patient cohort, CS provided no significant mortality benefit compared with medical therapy. Individual decision making by a "heart and endocarditis team" is necessary to offer those patients the most reasonable treatment option.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Development of Antibiotic Resistance
Antibiotic Selection
Endocarditis I: Introduction
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Endocarditis III: Medical Management

